Ameriprise Financial Inc. Buys 29,133 Shares of Hologic, Inc. $HOLX

Key Points

• Ameriprise Financial Inc. increased its stake in Hologic, Inc. by 0.8%, acquiring an additional 29,133 shares, which brings its total ownership to 3,512,594 shares valued at approximately $216.97 million.
• Analyst ratings for Hologic indicate a consensus rating of "Moderate Buy", with one analyst giving a "Strong Buy," eight a "Buy," and eight a "Hold" rating, alongside a consensus price target of $78.00.
• Hologic reported earnings per share of $1.08 for the last quarter, surpassing analysts' expectations, with revenue of $1.02 billion, reflecting a year-over-year increase of 1.2%.

Ameriprise Financial Inc. boosted its stake in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 0.8% in the 1st quarter, according to the company in its most recent disclosure with the SEC. The firm owned 3,512,594 shares of the medical equipment provider's stock after buying an additional 29,133 shares during the quarter. Ameriprise Financial Inc. owned approximately 1.58% of Hologic worth $216,973,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in HOLX. Zions Bancorporation National Association UT bought a new position in Hologic during the first quarter worth about $34,000. Allworth Financial LP boosted its position in Hologic by 46.0% during the first quarter. Allworth Financial LP now owns 686 shares of the medical equipment provider's stock worth $40,000 after purchasing an additional 216 shares during the period. Bank Julius Baer & Co. Ltd Zurich bought a new position in Hologic during the first quarter worth about $42,000. Larson Financial Group LLC boosted its position in Hologic by 6,016.7% during the first quarter. Larson Financial Group LLC now owns 734 shares of the medical equipment provider's stock worth $45,000 after purchasing an additional 722 shares during the period. Finally, Raiffeisen Bank International AG bought a new position in Hologic during the fourth quarter worth about $49,000. Institutional investors own 94.73% of the company's stock.

Wall Street Analyst Weigh In

HOLX has been the subject of a number of research reports. Mizuho set a $75.00 target price on shares of Hologic in a research report on Thursday, July 31st. UBS Group increased their target price on shares of Hologic from $65.00 to $70.00 and gave the stock a "neutral" rating in a research report on Thursday, July 31st. Royal Bank Of Canada upgraded shares of Hologic from a "sector perform" rating to an "outperform" rating and raised their price objective for the company from $72.00 to $87.00 in a research report on Wednesday, August 6th. Raymond James Financial restated an "outperform" rating and issued a $71.00 price objective (down from $90.00) on shares of Hologic in a research report on Friday, May 2nd. Finally, Needham & Company LLC restated a "hold" rating on shares of Hologic in a research report on Tuesday, May 27th. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and eight have given a Hold rating to the stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $78.00.

Hologic Price Performance

HOLX stock opened at $68.26 on Friday. The firm has a 50 day moving average of $65.90 and a 200-day moving average of $62.49. The company has a current ratio of 3.55, a quick ratio of 2.81 and a debt-to-equity ratio of 0.52. Hologic, Inc. has a 12 month low of $51.90 and a 12 month high of $84.39. The firm has a market capitalization of $15.18 billion, a P/E ratio of 28.32, a price-to-earnings-growth ratio of 2.44 and a beta of 0.49.

Hologic (NASDAQ:HOLX - Get Free Report) last announced its earnings results on Wednesday, July 30th. The medical equipment provider reported $1.08 earnings per share for the quarter, beating analysts' consensus estimates of $1.05 by $0.03. The business had revenue of $1.02 billion for the quarter, compared to the consensus estimate of $1.01 billion. Hologic had a net margin of 13.79% and a return on equity of 19.69%. Hologic's quarterly revenue was up 1.2% on a year-over-year basis. During the same period last year, the firm posted $1.06 earnings per share. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. As a group, sell-side analysts predict that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.

Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.